Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00014183 · ClinicalTrials.gov registry record · Phase 2
ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00014183 is a Phase 2 study that has completed, run by University of Maryland, Baltimore.
The verdict
NCT00014183, a Phase 2 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of kidney cancer. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have recurrent or stage IV kidney cancer.
Interventions
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-01 |
| Est. Completion | 2005-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00014183
The ClinicalTrials.gov registry entry for NCT00014183 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which gefitinib is the first listed.
NCT00014183 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00014183 about?
NCT00014183 is a clinical study titled "ZD 1839 in Treating Patients With Stage IV or Recurrent Kidney Cancer". RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of kidney cancer. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have recurrent or stage IV kidney cancer.
What is the current status of trial NCT00014183?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-01. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00014183?
The interventions under investigation include: gefitinib (DRUG).
Who is sponsoring clinical trial NCT00014183?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.